You are here: Home » Current Affairs » Coronavirus » News
Business Standard

DCGI nod to Phase-1 trials of 'antisera' with potential to treat Covid-19

The 'antisera' is yet to undergo human clinical trials to establish safety and efficacy

clinical trials | Coronavirus Tests | ICMR

Press Trust of India  |  New Delhi 

Coronavirus, covid, tests
The pre-print version of the study regarding the development of the equine antisera has been posted on the Research Square platform.

The Drugs Controller General of India has given permission for conducting Phase-1 human clinical trial for an "antisera" that was developed by injecting inactivated SARS-CoV-2 in horses and can be a potential treatment for Covid-19, officials said on Tuesday. The 'antisera' has been developed by the Indian Council of Medical Research (ICMR) in collaboration with a Hyderabad-based bio-pharmaceutical firm. "With Biological E Limited we have developed an horse 'antisera' and we have just got clearance for conducting for that," Director General Dr Balram Bhargava said at press briefing on Tuesday.

The 'antisera' is yet to undergo human to establish safety and efficacy. Antisera are blood serum high in antibodies against specific antigens and are injected in humans to help kickstart the immune system to fight specific infections. "The and Biological E Limited, Hyderabad, have developed highly purified antisera (raised in animals) for prophylaxis and treatment of Covid-19," the apex health research body had earlier said in a tweet.

The pre-print version of the study regarding the development of the equine antisera has been posted on the Research Square platform.

"The study provides evidence of the potential of generating highly purified F(ab')2 from equines against SARS-CoV-2 that can demonstrate consistent and high neutralisation activity," the study paper said.

"Further, in-vivo testing for efficacy of this indigenously developed, cost effective product will pave the way to clinical evaluation. Additionally, being a donor independent method, this may prove as an efficient alternative to convalescent plasma for treatment of Covid-19 patients," it said.

Earlier such measures were used for controlling several viral and bacterial infections.

"Although, plasma recovered from patients experiencing Covid-19 could serve similar purpose, the profile of antibodies, their efficacy and concentration keep varying from one patient to another and therefore, make it an unreliable clinical tool for patient management," the ICMR had said in a tweet. "Standardisation achievable through equine sera based treatment modality thus stands out as yet another remarkable public health initiative supported by ICMR in the time of Covid-19," it said.

As part of the study, 10 healthy horses were immunised with inactivated SARS-CoV-2 and after 21 days of immunisation, plasma samples were tested. The results of the plasma samples indicated presence of SARS-CoV-2 specific IgG antibodies as detected in ELISA with neutralising capacity.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, October 06 2020. 22:18 IST